封面
市場調查報告書
商品編碼
1691774

基於組學的臨床試驗市場 - 全球產業規模、佔有率、趨勢、機會和預測,按階段、按研究設計、按適應症、按地區和競爭進行細分,2020-2030 年預測

Omics-Based Clinical Trials Market - Global Industry Size, Share, Trends, Opportunity, and Forecast, Segmented By Phase, By Study Design, By Indication, By Region & Competition, 2020-2030F

出版日期: | 出版商: TechSci Research | 英文 180 Pages | 商品交期: 2-3個工作天內

價格

We offer 8 hour analyst time for an additional research. Please contact us for the details.

簡介目錄

2024 年全球基於組學的臨床試驗市場價值為 266.7 億美元,預計在預測期內將經歷大幅成長,到 2030 年的年複合成長率(CAGR) 為 7.25%。基於組學的臨床試驗整合了先進的組學技術,以收集參與臨床研究的患者的詳細分子資料。組學涵蓋了生物學和醫學中用於在分子水平上分析生物分子的一系列高通量技術。這些技術包括基因組學(研究基因和 DNA)、蛋白質組學(研究蛋白質)、代謝組學(研究小分子和代謝物)、轉錄組學(研究 RNA 和基因表現)等。基於組學的臨床試驗的一個主要目標是根據患者的分子特徵將其分成亞組,從而實現更有針對性和個性化的醫療干預。

市場概況
預測期 2026-2030
2024 年市場規模 266.7 億美元
2030 年市場規模 402.6 億美元
2025-2030 年複合年成長率 7.25%
成長最快的領域 干預性研究
最大的市場 北美洲

然而,基於組學的臨床試驗面臨資料標準化、可重複性問題以及對先進生物資訊能力的需求等挑戰。組學資料的準確性和可靠性對於試驗的成功至關重要。例如,2024 年 4 月發表的一篇文章強調了基於組學的生物標記在管理代謝功能障礙相關脂肪變性肝病 (MASLD) 方面日益成長的重要性,這些生物標記有助於風險分層和識別不良後果風險較高的晚期纖維化患者。基於組學的臨床試驗的日益普及預計將進一步推動市場成長。

主要市場促進因素:

組學技術的進步

主要市場挑戰:

樣本大小和多樣性

主要市場趨勢:

多組學資料整合

目錄

第 1 章:產品概述

第 2 章:研究方法

第 3 章:執行摘要

第 4 章:顧客之聲

第 5 章:全球基於組學的臨床試驗市場展望

  • 市場規模和預測
    • 按價值
  • 市場佔有率和預測
    • 按階段(第一階段、第二階段、第三階段和第四階段)
    • 依研究設計(擴大准入研究、介入性研究和觀察性研究)
    • 按適應症(心臟病學、中樞神經系統疾病、遺傳疾病、免疫學、腫瘤學、呼吸系統疾病和皮膚病)
    • 按地區
    • 按公司分類(2024)
  • 市場地圖

第 6 章:亞太地區基於組學的臨床試驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 亞太地區:國家分析
    • 印度
    • 澳洲
    • 日本
    • 韓國

第 7 章:歐洲基於組學的臨床試驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 歐洲:國家分析
    • 德國
    • 西班牙
    • 義大利
    • 英國

第 8 章:北美基於組學的臨床試驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 北美:國家分析
    • 墨西哥
    • 加拿大

第 9 章:南美洲基於組學的臨床試驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • 南美洲:國家分析
    • 阿根廷
    • 哥倫比亞

第 10 章:中東和非洲基於組學的臨床試驗市場展望

  • 市場規模和預測
  • 市場佔有率和預測
  • MEA:國家分析
    • 沙烏地阿拉伯
    • 阿拉伯聯合大公國

第 11 章:市場動態

  • 驅動程式
  • 挑戰

第 12 章:市場趨勢與發展

  • 最新動態
  • 產品發布
  • 合併與收購

第 13 章:全球基於組學的臨床試驗市場:SWOT 分析

第 14 章:波特五力分析

  • 產業競爭
  • 新進入者的潛力
  • 供應商的力量
  • 顧客的力量
  • 替代產品的威脅

第 15 章: 大環境分析

第 16 章:競爭格局

  • Parexel International Corporation
  • Pharmaceutical Product Development (PPD)
  • Charles River Laboratory
  • ICON plc
  • SGS SA
  • Eli Lilly and Company
  • Pfizer Inc.
  • Covance Inc.
  • Novo Nordisk
  • Rebus Bio

第 17 章:策略建議

第18章調查會社について,免責事項

簡介目錄
Product Code: 18961

The global Omics-Based Clinical Trials Market was valued at USD 26.67 billion in 2024 and is projected to experience substantial growth during the forecast period, with a compound annual growth rate (CAGR) of 7.25% through 2030. Omics-based clinical trials integrate advanced omics technologies to collect detailed molecular data from patients participating in clinical studies. Omics encompasses a range of high-throughput techniques used in biology and medicine to analyze biological molecules at the molecular level. These techniques include genomics (the study of genes and DNA), proteomics (the study of proteins), metabolomics (the study of small molecules and metabolites), transcriptomics (the study of RNA and gene expression), and more. A key objective of omics-based clinical trials is to stratify patients into subgroups based on their molecular profiles, enabling more targeted and personalized healthcare interventions.

Market Overview
Forecast Period2026-2030
Market Size 2024USD 26.67 Billion
Market Size 2030USD 40.26 Billion
CAGR 2025-20307.25%
Fastest Growing SegmentInterventional Studies
Largest MarketNorth America

However, omics-based clinical trials face challenges such as data standardization, reproducibility issues, and the need for advanced bioinformatics capabilities. The accuracy and reliability of omics data are crucial for successful trials. For example, an article published in April 2024 highlights the growing significance of omics-based biomarkers in managing metabolic dysfunction-associated steatotic liver disease (MASLD), where these biomarkers aid in risk stratification and identifying patients with advanced fibrosis who are at higher risk of adverse outcomes. The increasing adoption of omics-based clinical trials is expected to further propel market growth.

Key Market Drivers:

Advancements in Omics Technologies

Recent developments in high-throughput sequencing have made these techniques faster, more precise, and cost-effective. Technologies like single-cell sequencing enable the examination of genetic material at an individual cell level, revealing cellular heterogeneity. Mass spectrometry tools have become more sensitive and precise, allowing the identification and quantification of proteins and metabolites in complex biological samples. Additionally, advancements in mass spectrometry imaging (MSI) enable the spatial mapping of molecules within tissues. Cryo-electron microscopy (cryo-EM) has revolutionized the structural analysis of proteins, achieving near-atomic resolution. X-ray crystallography and nuclear magnetic resonance (NMR) spectroscopy continue to enhance molecular structure resolution. Technologies such as stable isotope labeling and flux analysis offer insights into metabolic pathways, while quantitative proteomics methods, including isobaric labeling and label-free approaches, allow precise protein quantification.

A report from the Mayo Clinic in February 2023 highlights a new approach in genomics research, shifting some omics studies from traditional settings like hospitals to individuals' homes, particularly in rural and underserved areas. This change is expected to improve access to clinical trials, expanding participant pools and enabling more diverse data collection.

Key Market Challenges:

Sample Size and Diversity

One of the challenges of omics-based clinical trials is obtaining an adequate number of patient samples, particularly for rare diseases or genetically specific subpopulations. The availability of diverse patient samples is crucial, as these trials often require large and varied cohorts to generate reliable results. Biological variability among patients within the same disease category can be substantial, making it necessary to include larger sample sizes for statistical validity. Furthermore, ensuring genetic and ethnic diversity in clinical trial populations is essential for the broader applicability of findings. Omics-based trials often involve subgroup analysis based on genetic or molecular characteristics, and recruiting patients that meet these specific criteria can be time-consuming and resource-intensive. Delays in recruitment and data collection can hinder the trial process. Additionally, obtaining informed consent for genetic and molecular profiling, as well as addressing privacy concerns, can also present challenges.

The integration and interpretation of large, complex omics data sets also require advanced bioinformatics tools, which can further complicate the analysis, especially when dealing with large and diverse sample sizes.

Key Market Trends:

Integration of Multi-Omics Data

Different omics technologies provide unique perspectives on the molecular mechanisms underlying diseases. Integrating data from multiple omics disciplines offers a more comprehensive view of disease processes by examining the interplay of genes, proteins, metabolites, and other factors. This integration enhances the identification and validation of biomarkers for disease diagnosis, prognosis, and treatment response. Combining genetic, proteomic, and metabolic profiles leads to more accurate and robust biomarker discovery.

The integration of multi-omics data is pivotal for patient stratification, allowing researchers to classify patients based on molecular profiles and design more targeted clinical trials. This approach also facilitates the development of personalized therapies tailored to individual genetic, proteomic, and metabolic characteristics, leading to more effective treatments. In drug development, multi-omics integration helps to understand how drugs interact with various molecular components, providing insights into potential adverse effects and guiding drug design. For complex diseases like cancer, multi-omics data integration aids in understanding intricate molecular interactions, facilitating the identification of novel therapeutic targets and strategies. This integration aligns with a systems biology approach, offering a holistic understanding of biological systems as interconnected networks of genes, proteins, and metabolites.

Key Market Players:

  • Parexel International Corporation
  • Pharmaceutical Product Development (PPD)
  • Charles River Laboratory
  • ICON plc
  • SGS SA
  • Eli Lilly and Company
  • Pfizer Inc.
  • Covance Inc.
  • Novo Nordisk
  • Rebus Bio

Report Scope:

This report segments the global omics-based clinical trials market into various categories and provides a comprehensive analysis of market trends:

By Phase:

  • Phase I
  • Phase II
  • Phase III
  • Phase IV

By Study Design:

  • Expanded Access Studies
  • Interventional Studies
  • Observational Studies

By Indication:

  • Cardiology
  • CNS Diseases
  • Genetic Diseases
  • Immunology
  • Oncology
  • Respiratory Diseases
  • Skin Diseases

By Region:

  • North America: United States, Canada, Mexico
  • Asia-Pacific: China, India, South Korea, Australia, Japan
  • Europe: Germany, France, United Kingdom, Spain, Italy
  • South America: Brazil, Argentina, Colombia
  • Middle East & Africa: South Africa, Saudi Arabia, UAE

Competitive Landscape:

This section provides detailed analysis and profiles of the major players in the global omics-based clinical trials market.

Available Customizations:

TechSci Research offers tailored customization options for this market report. These include a detailed analysis of additional market players (up to five) as per specific company needs.

Table of Contents

1. Product Overview

  • 1.1. Market Definition
  • 1.2. Scope of the Market
    • 1.2.1. Markets Covered
    • 1.2.2. Years Considered for Study
    • 1.2.3. Key Market Segmentations

2. Research Methodology

  • 2.1. Objective of the Study
  • 2.2. Baseline Methodology
  • 2.3. Key Industry Partners
  • 2.4. Major Association and Secondary Sources
  • 2.5. Forecasting Methodology
  • 2.6. Data Triangulation & Validation
  • 2.7. Assumptions and Limitations

3. Executive Summary

  • 3.1. Overview of the Market
  • 3.2. Overview of Key Market Segmentations
  • 3.3. Overview of Key Market Players
  • 3.4. Overview of Key Regions/Countries
  • 3.5. Overview of Market Drivers, Challenges, Trends

4. Voice of Customer

5. Global Omics-Based Clinical Trials Market Outlook

  • 5.1. Market Size & Forecast
    • 5.1.1. By Value
  • 5.2. Market Share & Forecast
    • 5.2.1. By Phase (Phase I, Phase II, Phase III, and Phase IV.)
    • 5.2.2. By Study Design (Expanded Access Studies, Interventional Studies, and Observational Studies)
    • 5.2.3. By Indication (Cardiology, CNS Diseases, Genetic Diseases, Immunology, Oncology, Respiratory Diseases, and Skin Diseases)
    • 5.2.4. By Region
    • 5.2.5. By Company (2024)
  • 5.3. Market Map

6. Asia Pacific Omics-Based Clinical Trials Market Outlook

  • 6.1. Market Size & Forecast
    • 6.1.1. By Value
  • 6.2. Market Share & Forecast
    • 6.2.1. By Phase
    • 6.2.2. By Study Design
    • 6.2.3. By Indication
    • 6.2.4. By Country
  • 6.3. Asia Pacific: Country Analysis
    • 6.3.1. China Omics-Based Clinical Trials Market Outlook
      • 6.3.1.1. Market Size & Forecast
        • 6.3.1.1.1. By Value
      • 6.3.1.2. Market Share & Forecast
        • 6.3.1.2.1. By Phase
        • 6.3.1.2.2. By Study Design
        • 6.3.1.2.3. By Indication
    • 6.3.2. India Omics-Based Clinical Trials Market Outlook
      • 6.3.2.1. Market Size & Forecast
        • 6.3.2.1.1. By Value
      • 6.3.2.2. Market Share & Forecast
        • 6.3.2.2.1. By Phase
        • 6.3.2.2.2. By Study Design
        • 6.3.2.2.3. By Indication
    • 6.3.3. Australia Omics-Based Clinical Trials Market Outlook
      • 6.3.3.1. Market Size & Forecast
        • 6.3.3.1.1. By Value
      • 6.3.3.2. Market Share & Forecast
        • 6.3.3.2.1. By Phase
        • 6.3.3.2.2. By Study Design
        • 6.3.3.2.3. By Indication
    • 6.3.4. Japan Omics-Based Clinical Trials Market Outlook
      • 6.3.4.1. Market Size & Forecast
        • 6.3.4.1.1. By Value
      • 6.3.4.2. Market Share & Forecast
        • 6.3.4.2.1. By Phase
        • 6.3.4.2.2. By Study Design
        • 6.3.4.2.3. By Indication
    • 6.3.5. South Korea Omics-Based Clinical Trials Market Outlook
      • 6.3.5.1. Market Size & Forecast
        • 6.3.5.1.1. By Value
      • 6.3.5.2. Market Share & Forecast
        • 6.3.5.2.1. By Phase
        • 6.3.5.2.2. By Study Design
        • 6.3.5.2.3. By Indication

7. Europe Omics-Based Clinical Trials Market Outlook

  • 7.1. Market Size & Forecast
    • 7.1.1. By Value
  • 7.2. Market Share & Forecast
    • 7.2.1. By Phase
    • 7.2.2. By Study Design
    • 7.2.3. By Indication
    • 7.2.4. By Country
  • 7.3. Europe: Country Analysis
    • 7.3.1. France Omics-Based Clinical Trials Market Outlook
      • 7.3.1.1. Market Size & Forecast
        • 7.3.1.1.1. By Value
      • 7.3.1.2. Market Share & Forecast
        • 7.3.1.2.1. By Phase
        • 7.3.1.2.2. By Study Design
        • 7.3.1.2.3. By Indication
    • 7.3.2. Germany Omics-Based Clinical Trials Market Outlook
      • 7.3.2.1. Market Size & Forecast
        • 7.3.2.1.1. By Value
      • 7.3.2.2. Market Share & Forecast
        • 7.3.2.2.1. By Phase
        • 7.3.2.2.2. By Study Design
        • 7.3.2.2.3. By Indication
    • 7.3.3. Spain Omics-Based Clinical Trials Market Outlook
      • 7.3.3.1. Market Size & Forecast
        • 7.3.3.1.1. By Value
      • 7.3.3.2. Market Share & Forecast
        • 7.3.3.2.1. By Phase
        • 7.3.3.2.2. By Study Design
        • 7.3.3.2.3. By Indication
    • 7.3.4. Italy Omics-Based Clinical Trials Market Outlook
      • 7.3.4.1. Market Size & Forecast
        • 7.3.4.1.1. By Value
      • 7.3.4.2. Market Share & Forecast
        • 7.3.4.2.1. By Phase
        • 7.3.4.2.2. By Study Design
        • 7.3.4.2.3. By Indication
    • 7.3.5. United Kingdom Omics-Based Clinical Trials Market Outlook
      • 7.3.5.1. Market Size & Forecast
        • 7.3.5.1.1. By Value
      • 7.3.5.2. Market Share & Forecast
        • 7.3.5.2.1. By Phase
        • 7.3.5.2.2. By Study Design
        • 7.3.5.2.3. By Indication

8. North America Omics-Based Clinical Trials Market Outlook

  • 8.1. Market Size & Forecast
    • 8.1.1. By Value
  • 8.2. Market Share & Forecast
    • 8.2.1. By Phase
    • 8.2.2. By Study Design
    • 8.2.3. By Indication
    • 8.2.4. By Country
  • 8.3. North America: Country Analysis
    • 8.3.1. United States Omics-Based Clinical Trials Market Outlook
      • 8.3.1.1. Market Size & Forecast
        • 8.3.1.1.1. By Value
      • 8.3.1.2. Market Share & Forecast
        • 8.3.1.2.1. By Phase
        • 8.3.1.2.2. By Study Design
        • 8.3.1.2.3. By Indication
    • 8.3.2. Mexico Omics-Based Clinical Trials Market Outlook
      • 8.3.2.1. Market Size & Forecast
        • 8.3.2.1.1. By Value
      • 8.3.2.2. Market Share & Forecast
        • 8.3.2.2.1. By Phase
        • 8.3.2.2.2. By Study Design
        • 8.3.2.2.3. By Indication
    • 8.3.3. Canada Omics-Based Clinical Trials Market Outlook
      • 8.3.3.1. Market Size & Forecast
        • 8.3.3.1.1. By Value
      • 8.3.3.2. Market Share & Forecast
        • 8.3.3.2.1. By Phase
        • 8.3.3.2.2. By Study Design
        • 8.3.3.2.3. By Indication

9. South America Omics-Based Clinical Trials Market Outlook

  • 9.1. Market Size & Forecast
    • 9.1.1. By Value
  • 9.2. Market Share & Forecast
    • 9.2.1. By Phase
    • 9.2.2. By Study Design
    • 9.2.3. By Indication
    • 9.2.4. By Country
  • 9.3. South America: Country Analysis
    • 9.3.1. Brazil Omics-Based Clinical Trials Market Outlook
      • 9.3.1.1. Market Size & Forecast
        • 9.3.1.1.1. By Value
      • 9.3.1.2. Market Share & Forecast
        • 9.3.1.2.1. By Phase
        • 9.3.1.2.2. By Study Design
        • 9.3.1.2.3. By Indication
    • 9.3.2. Argentina Omics-Based Clinical Trials Market Outlook
      • 9.3.2.1. Market Size & Forecast
        • 9.3.2.1.1. By Value
      • 9.3.2.2. Market Share & Forecast
        • 9.3.2.2.1. By Phase
        • 9.3.2.2.2. By Study Design
        • 9.3.2.2.3. By Indication
    • 9.3.3. Colombia Omics-Based Clinical Trials Market Outlook
      • 9.3.3.1. Market Size & Forecast
        • 9.3.3.1.1. By Value
      • 9.3.3.2. Market Share & Forecast
        • 9.3.3.2.1. By Phase
        • 9.3.3.2.2. By Study Design
        • 9.3.3.2.3. By Indication

10. Middle East and Africa Omics-Based Clinical Trials Market Outlook

  • 10.1. Market Size & Forecast
    • 10.1.1. By Value
  • 10.2. Market Share & Forecast
    • 10.2.1. By Phase
    • 10.2.2. By Study Design
    • 10.2.3. By Indication
    • 10.2.4. By Country
  • 10.3. MEA: Country Analysis
    • 10.3.1. South Africa Omics-Based Clinical Trials Market Outlook
      • 10.3.1.1. Market Size & Forecast
        • 10.3.1.1.1. By Value
      • 10.3.1.2. Market Share & Forecast
        • 10.3.1.2.1. By Phase
        • 10.3.1.2.2. By Study Design
        • 10.3.1.2.3. By Indication
    • 10.3.2. Saudi Arabia Omics-Based Clinical Trials Market Outlook
      • 10.3.2.1. Market Size & Forecast
        • 10.3.2.1.1. By Value
      • 10.3.2.2. Market Share & Forecast
        • 10.3.2.2.1. By Phase
        • 10.3.2.2.2. By Study Design
        • 10.3.2.2.3. By Indication
    • 10.3.3. UAE Omics-Based Clinical Trials Market Outlook
      • 10.3.3.1. Market Size & Forecast
        • 10.3.3.1.1. By Value
      • 10.3.3.2. Market Share & Forecast
        • 10.3.3.2.1. By Phase
        • 10.3.3.2.2. By Study Design
        • 10.3.3.2.3. By Indication

11. Market Dynamics

  • 11.1. Drivers
  • 11.2. Challenges

12. Market Trends & Developments

  • 12.1. Recent Developments
  • 12.2. Product Launches
  • 12.3. Mergers & Acquisitions

13. Global Omics-Based Clinical Trials Market: SWOT Analysis

14. Porter's Five Forces Analysis

  • 14.1. Competition in the Industry
  • 14.2. Potential of New Entrants
  • 14.3. Power of Suppliers
  • 14.4. Power of Customers
  • 14.5. Threat of Substitute Product

15. PESTLE Analysis

16. Competitive Landscape

  • 16.1. Parexel International Corporation
    • 16.1.1. Business Overview
    • 16.1.2. Company Snapshot
    • 16.1.3. Products & Services
    • 16.1.4. Financials (In case of listed companies)
    • 16.1.5. Recent Developments
    • 16.1.6. SWOT Analysis
  • 16.2. Pharmaceutical Product Development (PPD)
    • 16.2.1. Business Overview
    • 16.2.2. Company Snapshot
    • 16.2.3. Products & Services
    • 16.2.4. Financials (In case of listed companies)
    • 16.2.5. Recent Developments
    • 16.2.6. SWOT Analysis
  • 16.3. Charles River Laboratory
    • 16.3.1. Business Overview
    • 16.3.2. Company Snapshot
    • 16.3.3. Products & Services
    • 16.3.4. Financials (In case of listed companies)
    • 16.3.5. Recent Developments
    • 16.3.6. SWOT Analysis
  • 16.4. ICON plc
    • 16.4.1. Business Overview
    • 16.4.2. Company Snapshot
    • 16.4.3. Products & Services
    • 16.4.4. Financials (In case of listed companies)
    • 16.4.5. Recent Developments
    • 16.4.6. SWOT Analysis
  • 16.5. SGS SA
    • 16.5.1. Business Overview
    • 16.5.2. Company Snapshot
    • 16.5.3. Products & Services
    • 16.5.4. Financials (In case of listed companies)
    • 16.5.5. Recent Developments
    • 16.5.6. SWOT Analysis
  • 16.6. Eli Lilly and Company
    • 16.6.1. Business Overview
    • 16.6.2. Company Snapshot
    • 16.6.3. Products & Services
    • 16.6.4. Financials (In case of listed companies)
    • 16.6.5. Recent Developments
    • 16.6.6. SWOT Analysis
  • 16.7. Pfizer Inc.
    • 16.7.1. Business Overview
    • 16.7.2. Company Snapshot
    • 16.7.3. Products & Services
    • 16.7.4. Financials (In case of listed companies)
    • 16.7.5. Recent Developments
    • 16.7.6. SWOT Analysis
  • 16.8. Covance Inc.
    • 16.8.1. Business Overview
    • 16.8.2. Company Snapshot
    • 16.8.3. Products & Services
    • 16.8.4. Financials (In case of listed companies)
    • 16.8.5. Recent Developments
    • 16.8.6. SWOT Analysis
  • 16.9. Novo Nordisk
    • 16.9.1. Business Overview
    • 16.9.2. Company Snapshot
    • 16.9.3. Products & Services
    • 16.9.4. Financials (In case of listed companies)
    • 16.9.5. Recent Developments
    • 16.9.6. SWOT Analysis
  • 16.10.Rebus Bio
    • 16.10.1. Business Overview
    • 16.10.2. Company Snapshot
    • 16.10.3. Products & Services
    • 16.10.4. Financials (In case of listed companies)
    • 16.10.5. Recent Developments
    • 16.10.6. SWOT Analysis

17. Strategic Recommendations

18. About Us & Disclaimer